Novavax Is Up 127% Since My Bullish Call in June – Here’s Where It Could Go from Here

I’ve been bullish Novavax, Inc. (NASDAQ: NVAX) since June.

The stock is up 127% since then.

My only regret is that I didn’t inform you Junkies sooner…

That’s because NVAX is the hottest stock on Wall Street right now – up a mouthwatering 4,100% already this year.

finviz dynamic chart for  NVAX

But that doesn’t mean we still can’t continue to profit from the stock if it’s able to develop a working coronavirus solution…

On Tuesday, Novavax announced its potential vaccine to prevent COVID-19 (called NVX-CoV2373) generated promising immune responses in an early stage clinical trial.

The phase one trial included 131 healthy participants between the ages 18 and 59 at two sites in Australia.

Novavax said 106 participants received one of four dose levels of the potential vaccine. The remaining 25 patients received a placebo.

Participants received two doses of the potential vaccine via intramuscular injection approximately 21 days apart.

The vaccine produced neutralizing antibodies, which researchers believe are necessary to build immunity to the virus and “killer T-cells.”

Additionally, the neutralizing antibodies that were produced were higher than those seen in people who have recovered from COVID-19.

Novavax said the vaccine was well tolerated with no serious adverse effects reported. Most patients reported tenderness and pain at the injection after the first dose. Some also reported headaches, fatigue or muscle aches.

Only one participant in the trial experienced a mild fever after a second dose, the company said.

Earlier media reports and analysts cited eight possible hospitalizations related to the study. But Novavax clarified those false reports, explaining no patients were in fact hospitalized.

The stock initially fell on these incorrect safety concerns. But then it rocketed as much as 20% high on Wednesday.

Where NVAX Stock Could Head from Here

Last month, the United States government announced it would pay Novavax $1.6 billion to develop and manufacture the potential vaccine.

As part of the Trump administration’s “Operation Warp Speed” initiative, the aim is to deliver 100 million doses by the beginning of next year.

The money will also cover the cost of running a late-stage trial for Novavax, which could begin as early as October.

The company has said it would begin a phase two trial in multiple countries if the early stage trial was successful. 

I’ll keep you updated when that happens. And if it is successful, it wouldn’t surprise me to see the stock shoot 5X higher from current levels.

In the meantime, here’s another stock that could 10X from here…

Legendary Stock-Picker Predicts Next 1,000% Stock

He's pinpointed dozens of stocks that went on to jump 100% or more.

Plus 18 recommendations that skyrocketed over 1,000%.

Today, he's doing it all over again.

EV Play No One's Talking About

This company is a sneaky EV play that no one’s talking about. They’re producing the “oil” of electric vehicles and could hand big returns to the first movers.

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$30 Stock Freaking Out Billionaires

This stock is an industry leader in a robotics technology that is freaking out billionaires (trading for just $30).

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

The Best TaaS Stock Right Now

This company is set to corner the market in a self-driving technology that  could fundamentally change our entire society – much like the internet did.

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Up to 20,000 IPOs All in One Day

A radical $2.1 quadrillion shift is coming to the financial markets.

Some are calling it G.T.E. and Mark Cuban, Elon Musk, Richard Branson, and even banks like J.P. Morgan are invested in the tech behind it.

Just $25 could get you in alongside these billionaires. 

Enter your email address to receive the video that reveals it all.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$2 Biotech Stock

Steve Cohen, the billionaire stock picker known for running one of the most successful hedge funds ever, has poured millions into the first stock, and it’s trading for only $2.

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works